Pharmathen International S.A. 11/21/2025 483
Similar Posts
FDA requires expanded labeling about weight loss risk in patients younger than 6 years taking extended-release stimulants for ADHD
The U.S. Food and Drug Administration (FDA) is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD) – including certain formulations of amphetamine and methylphenidate – to warn about the risk of weight loss and other adverse reaHON-E-LING may be harmful due to hidden drug ingredients
HON-E-LING may be harmful due to hidden drug ingredientsWells Pharmacy Inc. Dyersburg, TN. 483 issued 04/25/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 04/25/2025
Short Title (70 char) Wells Pharmacy Inc. Dyersburg, TN. 483 issued 04/25/2025
FEI Number 3011761321
Firm Name Wells Pharmacy Inc.
Record Type 483
State TN
Establishment Type Outsourcing FacilityClinical Outcome Assessment (COA): Frequently Asked Questions
Clinical Outcome Assessments (COA) Frequently Asked QuestionsFDA Publishes Filing Checklists to Prevent Submission Delays
The U.S. Food and Drug Administration today made public filing checklists used internally by Center for Drug Evaluation and Research (CDER) staff to determine if a submitted application is complete and reviewable.Approved Drugs: Questions and Answers
How is a medicine approved by FDA?, How can I find out if my medicine is approved by FDA?